The effect of Pentoxifylline in patients with Covid-19

INTERVENTION: Intervention 1: Intervention group: Pentoxifylline with a dose of 400 mg, made by Farabi Pharmaceutical Company, Iran, was prescribed to patients weighing less than 70 kg every 12 hours and to patients weighing more than 70 kg every 8 hours. This group receives only Pentoxifylline for two days from the hospitalization day. Intervention 2: Control group: Vitamin D3 (oral capsule) with a dose of 50,000 units, one capsule at hospitalization day, hydroxychloroquine tablets with a dose of 200 mg every 12 hours for two days from the hospitalization day, serum therapy (2.5 to 3.5 liters) and Nasal Prong two to eight liters (depending on the patient's dyspnea condition) were prescribed. CONDITION: COVID‐19. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Oxygen saturation of arterial blood. Timepoint: Before intervention, daily after intervention. Method of measurement: Pulse‐oximeter monitoring. SECONDARY OUTCOME: Mortality. Timepoint: 7, 14, 21 and 28 days after intervention. Method of measurement: Clinical examination by physician and confirmation of death. Refer to the intensive care unit. Timepoint: 7, 14, 21 and 28 days after intervention. Method of measurement: Clinical Frailty Scale. INCLUSION CRITERIA: Clinical signs of fever (above 38.3 °C), dyspnea and cough Definite diagnosis of of Covid‐19 based on RT‐PCR